The unique treatment protocols of well-known doctors like Peter Attia are a form of intellectual property. These could be licensed and scaled through AI agents, allowing regular doctors to implement specialized, evidence-adjacent care plans without patients needing to see the expert directly.
Related Insights
With digital twins for drug testing and local 3D printing of drugs, pharma's role could shift from mass manufacturing to licensing molecule formulas. A doctor would test a drug on a digital twin and a pharmacy would print the personalized dose on site.
The next evolution in personalized medicine will be interoperability between personal and clinical AIs. A patient's AI, rich with daily context, will interface with their doctor's AI, trained on clinical data, to create a shared understanding before the human consultation begins.
As AI allows any patient to generate well-reasoned, personalized treatment plans, the medical system will face pressure to evolve beyond rigid standards. This will necessitate reforms around liability, data access, and a patient's "right to try" non-standard treatments that are demonstrably well-researched via AI.
The relationship between AI startups and pharma is evolving rapidly. Previously, pharma engaged AI firms on a project-by-project, consulting-style basis. Now, as AI models for drug discovery become more robust, pharma giants are seeking to license them as enterprise-wide software suites for internal deployment, signaling a major inflection point in AI integration.
Instead of replacing experts, AI can reformat their advice. It can take a doctor's diagnosis and transform it into a digestible, day-by-day plan tailored to a user's specific goals and timeline, making complex medical guidance easier to follow.
Reframe IP from a legal asset to be protected into your 'intellectual perspective'—a unique viewpoint on how to do something. This mindset shifts focus from costly legal protection to creating shareable, repeatable frameworks that scale your business beyond your personal involvement.
Instead of replacing doctors, AI will serve as a force multiplier for scarce General Practitioners. By automating paperwork and answering repetitive patient questions, AI frees doctors to focus on high-value human interaction and complex diagnosis.
AI tools allow any creative individual to invent and market entire fictional personas. This isn't just a marketing tactic; it's an opportunity to create and own valuable intellectual property (IP), much like a modern-day Walt Disney or Vince McMahon.
An LLM successfully solved a toddler's sleep problem, a task that previously required a human consultant charging hundreds of dollars per hour. This demonstrates AI's immediate power to democratize specialized expertise. It synthesizes vast knowledge to provide personalized, actionable advice for a fraction of the cost of a human professional.
Companies developing effective AI-powered workflows and system prompts are creating a new form of valuable IP. Instead of keeping these internal processes secret, they can be packaged as 'playbooks' and licensed to other businesses, generating a new, scalable stream of passive income.
